HealthEquity, Inc. $HQY Shares Purchased by Amundi

Key Points

• Amundi significantly increased its stake in HealthEquity, Inc. (HQY) by acquiring 27,625 additional shares, raising its total holdings to $2.29 million.
• Institutional investors hold 99.55% of HealthEquity's stock, indicating strong institutional interest and confidence in the company's prospects.
• HealthEquity's stock has received multiple upgrades from analysts, with target prices now ranging from $115.00 to $134.00, and a consensus rating of "Buy".

Amundi increased its position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 690,625.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,629 shares of the company's stock after purchasing an additional 27,625 shares during the period. Amundi's holdings in HealthEquity were worth $2,292,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of HQY. Invesco Ltd. boosted its position in shares of HealthEquity by 50.6% during the 1st quarter. Invesco Ltd. now owns 2,446,198 shares of the company's stock worth $216,171,000 after acquiring an additional 821,425 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in HealthEquity by 1.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,100,970 shares of the company's stock valued at $97,293,000 after purchasing an additional 14,159 shares in the last quarter. Stephens Investment Management Group LLC boosted its holdings in HealthEquity by 1.8% in the first quarter. Stephens Investment Management Group LLC now owns 1,069,446 shares of the company's stock valued at $94,507,000 after purchasing an additional 19,009 shares in the last quarter. Wellington Management Group LLP boosted its holdings in HealthEquity by 24.9% in the first quarter. Wellington Management Group LLP now owns 848,940 shares of the company's stock valued at $75,021,000 after purchasing an additional 169,337 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. boosted its holdings in HealthEquity by 10.1% in the first quarter. Vaughan Nelson Investment Management L.P. now owns 835,413 shares of the company's stock valued at $73,826,000 after purchasing an additional 76,950 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company's stock.

Insider Buying and Selling at HealthEquity

In related news, EVP Michael Henry Fiore sold 1,794 shares of the stock in a transaction on Monday, July 7th. The stock was sold at an average price of $101.73, for a total transaction of $182,503.62. Following the completion of the sale, the executive vice president directly owned 53,225 shares of the company's stock, valued at $5,414,579.25. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on HQY. Barrington Research restated an "outperform" rating and issued a $125.00 target price on shares of HealthEquity in a report on Friday, August 29th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, June 5th. The Goldman Sachs Group upped their price objective on shares of HealthEquity from $94.00 to $104.00 and gave the company a "neutral" rating in a research note on Wednesday, June 4th. Bank of America upped their price objective on shares of HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $120.00 target price (up from $115.00) on shares of HealthEquity in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $119.77.

HealthEquity Stock Performance

Shares of HQY traded up $0.74 during mid-day trading on Wednesday, hitting $92.28. 737,118 shares of the company's stock were exchanged, compared to its average volume of 1,215,614. HealthEquity, Inc. has a fifty-two week low of $74.07 and a fifty-two week high of $116.65. The business's 50 day moving average is $92.90 and its two-hundred day moving average is $94.19. The company has a current ratio of 4.23, a quick ratio of 4.23 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $7.95 billion, a P/E ratio of 55.93, a P/E/G ratio of 1.31 and a beta of 0.50.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.